NorDiag gets licenses p53 and APC markers:
This article was originally published in Clinica
Executive Summary
Bergen, Norway-based NorDiag, part of the Novel Diagnostics group, has formed a licensing agreement with Genzyme Corporation for access to the latter's p53 and APC genes. The additional gene markers will be incorporated into NorDiag's Genefec assay test for the early detection of colon cancer. Genefec is a noninvasive colorectal cancer test that uses faecal samples as the specimen. "These extra markers will further increase our assay's sensitivity, making it an even better tool for both diagnostic and public screening programmes," said NorDiag's chairman, Christian Horn.